10 presentations not to miss from SABCS 2024 suggested by Paolo Tarantino

The SABCS 2024 (San Antonio Breast Cancer Symposium) will take place from December 10th to 13th, 2024 at the Henry B. Gonzalez Convention Center in San Antonio, TX, USA

SABCS is expected to attract around 10,000+ attendees from more than 102 countries, including oncologists, researchers, and healthcare professionals.

This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

San Antonio Breast Cancer Symposium 2024 Top 10 Abstracts suggested by Paolo Tarantino

1. EMBER-3 (K. Jhaveri et al.) → Will the promising phase 1 data seen with imlunestrant (+/- abema) translate into improved outcomes for HR+/HER2- MBC? If positive, EMBER-3 could take the second oral SERD to the clinic, providing further second line treatment options for the most common MBC subtype.

2. KN522 biomarkers (J. O’Shaughnessy et al.) → The KN522 regimen saves lives, but also an overtreatment for many TNBC patients. This presentation will hopefully refine patient selection for this intense regimen.

3. ZEST (N. Turner et al.) → ctDNA surveillance is rapidly expanding in breast oncology, yet we still have no data suggesting that changing treatment based on ctDNA improves outcomes. The ZEST phase 3 trial explored the role of adjuvant niraparib if ctDNA becomes positive in BRCA-mutated breast cancer.

4. GeparDouze (C. Geyer et al.) → The role of atezo in eTNBC remines unclear, with positive pCR data from IMp031, but several negative phase 3 trials. GeparDouze, powered for PCR/EFS, will hopefully bring clarity.

5. MARGOT (A. Waks et al.) → Margetuximab improves PFS over trastuzumab in HER2+ MBC. Could an earlier use of this enhanced trastuzumab improve pCR rate and lead to better outcomes for HER2+ early BC?

6. SOLTI VALENTINE (M. Oliveira et al.) → HER3-DXd is highly active for ER+ MBC, and has also shown promise in the early setting. This neoadjuvant trial will build on the foundation of TOT-HER3, exploring the activity of neoadjuvant HER3-DXd (+/- letrozole) in patients with high-risk HR+ early breast cancer.

7. EUROPA (I. Meattini et al.)→ Elderly patients with small, luminal BC represent one of the largest population of patients we see in clinical practice. Could these patients get away with few weeks of post- surgical partial breast irradiation, avoiding the side effects of prolonged endocrine treatment?

8. Neoadjuvant dostarlimab/niraparib (E. Mayer et al.)→ Both olaparib and talazoparib showed relevant neoadjuvant activity in BRCAmut patients with breast cancer. Could the addition of immunotherapy (dostarlimab) further boost the activity of neoadjuvant PARP inhibitors (niraparib) for BRCA/PALB2mut patients?

9. Neoadjuvant SHR-A1811 for HER2+ BC (Z. Liu et al.) → T-DXd has revolutionized the way we treat HER2+ MBC. SHR-A1811, a HER2 ADC with many similarities to T-DXd, has also shown impressive activity in the metastatic setting. These data on its neoadjuvant use may anticipate what we may see next year from DB11.

10. NRG-BRO04 (V. Valero et al.) → Immunotherapy works best when used early. With this rationale, NRG- BRO04 tested the addition of atezolizumab to the CLEOPATRA 1L regimen for HER2+ MBC. It was unfortunately stopped due to imbalance in fatal adverse events. At SABCS24 we will finally see the full data.”

About Paolo Tarantino

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

Further Reading:

The San Antonio Breast Cancer Symposium (SABCS) 2024

SABCS’s Social Media Ambassadors 2024